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Influenza is a contagious respiratory acute viral disease charac-
terized by a short incubation period, high fever and respiratory 
and systemic symptoms.
The burden of influenza is very heavy. Indeed, the World Health 
Organization (WHO) estimates that annual epidemics affect 
5-15% of the world’s population, causing up to 4-5 million severe 
cases and from 250,000 to 500,000 deaths.
In order to design anti-influenza molecules and compounds, it 
is important to understand the complex replication cycle of the 
influenza virus. Replication is achieved through various stages. 
First, the virus must engage the sialic acid receptors present on 
the free surface of the cells of the respiratory tract. The virus 
can then enter the cells by different routes (clathrin-mediated 
endocytosis or CME, caveolae-dependent endocytosis or CDE, 
clathrin-caveolae-independent endocytosis, or macropinocyto-
sis). CME is the most usual pathway; the virus is internalized 
into an endosomal compartment, from which it must emerge in 
order to release its nucleic acid into the cytosol. The ribonucleo-
protein must then reach the nucleus in order to begin the pro-
cess of translation of its genes and to transcribe and replicate 
its nucleic acid. Subsequently, the RNA segments, surrounded 
by the nucleoproteins, must migrate to the cell membrane in 
order to enable viral assembly. Finally, the virus must be freed 
to invade other cells of the respiratory tract. All this is achieved 
through a synchronized action of molecules that perform multi-
ple enzymatic and catalytic reactions, currently known only in 
part, and for which many inhibitory or competitive molecules 
have been studied. Some of these studies have led to the devel-
opment of drugs that have been approved, such as Amantadine, 
Rimantadine, Oseltamivir, Zanamivir, Peramivir, Laninamivir, 
Ribavirin and Arbidol. This review focuses on the influenza life-
cycle and on the currently available drugs, while potential anti-
viral compounds for the prevention and treatment of influenza 
are considered in the subsequent review.
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Summary
Introduction
Influenza is a contagious acute respiratory viral disease 
characterized by a short incubation period, high fever, 
respiratory (e.g. runny and stuffy nose) and systemic 
symptoms (e.g. muscle or body aches) [1]. Most of the 
people affected by influenza recover in a few days or, 
at most, in 2 weeks. However, some patients may de-
velop complications that may be very serious. The most 
common complications are bronchitis, pneumonia, ear 
infections, etc. People with underlying diseases, such as 
asthma, subjects with Chronic Obstructive Pulmonary 
Disease (COPD) or individuals with heart disease are at 
high risk of complications  [2]. Related complications, 
such as myositis, acute encephalopathy or Reye’s syn-
drome, are rare [3]. Reye’s syndrome is classically char-
acterized by rashes, vomiting and liver damage. It can 
typically occur during viral illness in children who have 
been taking aspirin for a long period [4]. 
Pneumonia can be caused by bacterial superinfection also 
called secondary pneumonia or viral pneumonitis  [5, 6]. 
This is characterized by the complex interactions of 
host-co-infecting pathogens [7], and, in particularly frail 
and debilitated subjects, can result in the impairment of 
physical capabilities, dysregulation of immune respons-
es and a delayed return to homeostasis [5, 6]. 
The burden of influenza is very heavy. Indeed, the 
World Health Organization (WHO) estimates that an-
nual epidemics affect 5-15% of the world’s population, 
causing up to 4-5 million severe cases and from 250,000 
to 500,000 deaths [7]. The European Centre for Disease 
Prevention and Control (ECDC) estimates that approxi-
mately 10% of Europeans are infected each year  [8]. 
Furthermore, the US government estimates that 5-20% 
of US residents catch influenza each year [9]. 
Influenza viruses belong to the Ortomyxoviridae fam-
ily  [10], with the other two genera being Isavirus and 
Thogotovirus, and have the ability to change their sur-
face antigens relatively frequently [11]. When a major 
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variation occurs, if the virus adapts to humans during 
zoonotic spill-over, widespread diffusion of the virus is 
possible, resulting in a pandemic [12]. The most severe 
influenza pandemic was that of 1918, which caused 500 
million cases and from 50 to 100 million deaths [13, 14]. 
During that devastating pandemic, the treatment of pa-
tients suffering from influenza was empirical and symp-
tomatic, and was intended primarily to relieve fever and 
pain (e.g. aspirin administration), while epinephrine was 
used to treat forms of secondary pneumonia  [15]. Only 
in the 1960s did the first antiviral drug against influenza, 
namely Amantadine, become available in the US [16, 17], 
while in 1993 another drug, Rimantadine, was author-
ized [18]. Later, in 1999, the anti-neuraminidase (NA) 
medications Zanamivir and Oseltamivir were both li-
censed in the US [19]. 
Since 1999, much knowledge concerning viral replica-
tion has been acquired, and new experimental hypoth-
eses have been advanced for the development of new 
flu drugs and new protocols for both prevention and 
treatment. Anti-influenza drugs are an important com-
plement to vaccination, which is the most efficacious 
weapon against the disease. In this review, it therefore 
seemed useful to deal with the issue of new/potential 
antiviral medications against influenza infections, espe-
cially in the light of the most recent scientific advances.
Biology of influenza viruses 
Regarding the antigenic characteristics of the core pro-
teins (nucleoproteins [NP] and Matrix proteins [M pro-
teins]), three influenza virus types have been identified: 
A, B and C. Given the relevance of Influenza A Virus 
(IAV) to human pathology, we will provide a brief over-
view of its biology and life-cycle and underline the main 
differences among the three virus types in terms of struc-
tural and molecular biology.
The IAV particle varies in the range of 80-120 nm and 
is pleomorphic, being usually spherical, though cord-
like forms with a diameter of 40-100 nm and a length 
in the range of 300 nm-20 µm can occur  [11, 20, 21]. 
Transition from spherical to tubular form is not well 
understood: what is known so far is that M1  [22, 23], 
M2 [23, 24] and NP [25] could play a role in determin-
ing and modulating this process. Besides genetic traits, 
also the phenotype of the host cell, in terms of shape and 
polarization, seems to influence the viral form [21, 26]. 
Influenza B has a similar shape, being structurally in-
distinguishable from IAV [11], while Influenza C virus 
is usually filamentous and 500 nm long [11]. The IAV 
viral particle is an envelope made up of lipid rafts and 
spikes of two main types of glycoproteins: hemaggluti-
nin (HA) accounts for about 80% (about 500 molecules) 
and NA for about 17% (about 100 molecules); M2 is 
the least abundant protein, with only 16-20 copies per 
virion [11, 27]. 
The particle of influenza B virus contains four pro-
teins, namely HA, NA, NB, and BM2  [11,  28], while 
the particle of influenza C virus is made up of a major 
surface glycoprotein (HEF, hemagglutinin-esterase-fu-
sion protein) and a minor surface glycoprotein (CM2). 
These surface glycoproteins form ordered hexagonal ar-
rays [11, 29-32].
Underneath the viral membrane, M1 tightly binds the 
vRNPs, which consist of RNA strands (usually single 
strands but in certain cases double strands) [11] wrapped 
around NP and NEP, with a terminal polymerase ternary 
complex (PA, PB1, PB2). The genome is small (about 
13-16 kilobases) and contains seven or eight pieces of 
segmented negative-sense RNA (eight segments for 
IAV and influenza B, seven for influenza C), each piece 
of RNA containing either one or two genes of 890 to 
2,341 nucleotides each  [11]. The genome codes for at 
least 11 proteins: hemagglutinin (HA) of about 76-77 
kDa, NA of about 60 kDa, NP of about 60 kDa, M1 of 
about 28 kDa, M2 of about 15 kDa, non-structural pro-
tein type 1 (NS1) of about 26 kDa, non-structural protein 
type 2 (NS2) (also known as NEP: nuclear export pro-
tein) of about 11 kDa, PA of about 85 kDa, PB1 (poly-
merase basic type 1) of about 88 kDa, PB1-F2 of about 
80 kDa [33-35] and PB2 (polymerase basic type 2) of 
about 91 kDa [36]. 
In particular, segments 1-3 code for the ternary polymer-
ase complex (PB1, PB2 and PA, respectively), segment 
4 for HA, segment 5 for NA, segment 6 for NP, seg-
ment 7 for the matrix proteins, and segment 8 for the 
non-structural proteins  [11]. On the basis of the gene 
structures, segments can be divided into three classes: 
intronless, intron-containing and unspliced, and intron-
containing and spliced. On the basis of the kinetics of the 
gene expression, they can be classified into “early” (seg-
ments 1-3, 5 and the unspliced segment 8 transcript) and 
“late” (segments 4, 6, 7 and spliced segment 8) classes. 
Usually, structural and functional/kinetic classifications 
do not correspond [37, 38].
Moreover, the presence of overlapping genes and dif-
ferent splicing mechanisms may give rise to further ac-
cessory proteins, such as PB1-N40 [39], PA-X [39-40], 
PA-N155 [41], PA-N182 [42], M42 [43], and NS3 [43], 
which have been discovered and characterized only re-
cently. Another accessory protein, NEG8 ORF, has been 
predicted [44].
The viral proteome thus reveals unexpected dynamism 
and complexity  [43-44]; Matsuoka and coll. have de-
signed a comprehensive map of influenza interactions, 
termed FluMap, which contains 960 factors and 456 re-
actions as of April 2012 [47].
Replication cycle of influenza viruses 
The replication cycle of the virus (Fig. 1) is a complex, 
highly dynamic, biological process which consists of 
the following steps: 1) attachment of the virion to target 
cells and receptor binding (virus adsorption); 2) inter-
nalization into cellular regions by means of clathrin-me-
diated endocytosis (CME), caveolae-dependent endocy-
tosis (CDE), clathrin-caveolae-independent endocyto-
sis, and macropinocytosis; 3) endosomal trafficking via 
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endosomes / caveosome / macropinosome / lysosomes 
to the perinuclear compartment; 4) pH-dependent fu-
sion of viral and endosomal / organellar membranes; 5) 
uncoating; 6) nuclear importation; 7) transcription and 
replication; 8) nuclear exportation; 9) protein synthesis; 
10) post-translational processing and trafficking; 11) vi-
ral progeny assembly and packaging; 12) budding; and 
13) release (modified from [48]).
The cells infected by the influenza virus are: alveolar 
and bronchial epithelial tissue (BET) cells, alveolar mac-
rophages (AM), lung epithelial tissue (LET) cells and, in 
particular, type II pneumocytes, plasmacytoid dendritic 
cells (pDCs) and natural killer cells (NKs) [49, 50].
Influenza virus is able to activate Endoplasmic Reticu-
lum (ER) stress, caspase pathway [51] or to finely tune 
host secreted molecules, such as lung mucins [52], in or-
der to avoid being trapped and subsequently eliminated. 
Moreover, it recruits host factors and misuses them [53]. 
Although the mechanisms of influenza virus replica-
tion are not fully understood, scientific projects for new 
drugs against influenza cannot ignore the biological cy-
cle of this virus.
Influenza virus entry
The first important event during infection in humans is 
the attachment of influenza virions to the apical cell sur-
face (event known also as virus adsorption). Indeed, the 
entry of the Influenza virus into target cells is an essen-
tial process whereby viral genomes are delivered from 
extracellular virions to sites of transcription/replication 
in the cell nucleus [54]. During this phase, thanks to the 
surface glycoprotein HA, the virus interacts with (-2,3)- 
or (-2,6)-linked sialic acid receptors [55]. The physico-
chemical conformation of these receptors is not identical 
in different species of animals –  humans, seals, birds, 
pigs, horses, etc., which are the natural reservoir of the 
virus. The vast majority of human receptors are located 
in the upper respiratory tract, but man also possesses re-
ceptors typical of birds, which are located deep in the 
respiratory tract [56]. 
Fig. 1. Schematic representation of the replication cycle of the influenza: 1) attachment of the virion to target cells and receptor binding 
(virus adsorption); 2) internalization into cellular regions by means of clathrin-mediated endocytosis (Cme), caveolae-dependent endocy-
tosis (Cde), clathrin-caveolae-independent endocytosis, and macropinocytosis; 3) endosomal trafficking via endosomes / caveosome / 
macropinosome / lysosomes to the perinuclear compartment; 4) ph-dependent fusion of viral and endosomal / organellar membranes; 5) 
uncoating; 6) nuclear importation; 7) transcription and replication; 8) nuclear exportation; 9) protein synthesis; 10) post-translational pro-
cessing and trafficking; 11) viral progeny assembly and packaging; 12) budding; and 13) release. For further details, the reader is referred 
to the text. 
R. GASPARINI et Al.
72
HA is a homotrimeric integral type 1 membrane cyl-
inder-like glycoprotein, approximately 13.5 nanome-
tres long. HA monomers are synthesized as precursors 
(HA0) containing a hydrophobic signal sequence. Af-
ter being translated, they are glycosylated and cleaved 
into two smaller subunits: namely, HA1 of 50 kDa and 
HA2 of 27 kDa, which are linked by a disulfide bridge. 
Each subunit is characterized by a long, central, α-helix 
connected to the membrane by HA2 and surmounted by 
HA1, a spherical head containing the sialic acid binding 
sites (receptor binding sites or RBSs, also known as re-
ceptor binding pocket or RBP) [57]. The apolar domain 
of HA2, near the cleavage site, is known as the “fusion 
peptide” or HAfp23 [58, 59], since it is characterized by 
a domain of highly conserved N-terminal 23 residues. 
HAfp23 has a helical-hairpin structure consisting of two 
tightly-packed helices, which are fundamental to induc-
ing the negative curvature (“fusogenic conformation” of 
HA) [60].
There are at least eighteen HA subtypes [61]. These are 
further subdivided into two groups: group 1 comprises 
H1, H2, H5, H6, H8, H9, H11, H12, H13, H16, H17, and 
H18 (from waterfowl, the last two having been recent-
ly isolated from bats in Guatemala and Peru) [61, 62]; 
group 2 comprises H3, H4, H7, H10, H14, and H15 [62].
However, a recent experiment has proved that the virus 
can also enter into cells whose surface has been com-
pletely depleted of sialic acid-based glycoproteins and 
glycolipids [63]. This seems to suggest alternative entry 
routes. Indeed, H17 and H18 do not bind to sialic acid 
and their receptor is still unknown [64].
Entry is essentially through receptor-mediated endo-
cytosis  [65], though an alternative uptake pathway, 
namely macropinocytosis, has quite recently been dis-
covered [66-68]. Receptor-mediated endocytosis can be 
CME or mediated by lipid rafts: CDE or non-clathrin 
non-caveolae endocytosis [69-71]. 
CME is the most common pathway through which the 
virion is internalized. The clathrin triskelion is made up 
of three heavy chains, which constitute the backbone 
of the polyhedral structure, and of three light chains, 
which finely tune the assembly / disassembly of the 
triskelion [72]. Adaptor proteins, such as AP-2 [73], ep-
sin-1  [74], epsin-15, recognize specific internalization 
signals located on cargo receptors, and take part in the 
formation of clathrin-coated pits (CCPs). 
Caveolae are small flask-like infoldings of the mem-
brane, with high levels of cholesterol and glycosphin-
golipids and with caveolin as the integral membrane 
scaffolding structure. The remaining entry routes have 
been investigated less. In clathrin caveolae-independent 
endocytosis, the Ras-phosphoinositide 3-kinase (PI3K) 
signalling pathway may play a major role [75]. 
The PI3K inactive complex (PI3K p110-p85 heterodi-
mer) moves to the plasma membrane, where the SH2 
(Src Homology 2) domains of p85 engage the phospho-
tyrosine residues present in receptor-associated proteins, 
causing a molecular rearrangement of the complex, in 
such a way that p110 is now enzymatically active and 
can recruit / produce intracellular second messenger, 
such as PtdIns(3,4,5)P3 (phosphatidylinositol-(3,4,5)-
trisphosphate), from PtdIns(4,5)P2 (phosphatidylinosi-
tol-(4,5)-bisphosphate). Subsequently, several effector 
proteins with pleckstrin homology (PH) domains me-
diate an array of different signalling cascades: namely, 
activation of Akt, mTOR (mammalian Target Of Rapa-
mycin), PKC (Protein Kinase C), PTEN (Phosphatase 
and tensin homolog) pathways [76].
Macropinocytosis can be activated by cell growth factors 
such as the Epidermal Growth Factor (EGF) or Nerve 
Growth Factor (NGF) or can be induced by phorbol es-
ters. Macropinocytosis is Rac1-, PAK1- (p21-activated 
kinase type 1), cholesterol- and actin-dependent, since it 
extensively reorganizes the plasma membrane and implies 
energy mechanisms, such as Na+/H+ exchanger (NHE) 
activity [77, 78]. Also other pathogens such as Ebolavi-
rus  [79, 80], arenavirus  [81], adenovirus  [82, 83], HPV 
(Human Papillomavirus) [84], HIV (Human Immunode-
ficiency Virus) [85], Escherichia coli [86], Trypanoso-
ma cruzi [87], vaccinia virus [88], African Swine Fever 
virus [89], RSV (Respiratory Syncytial Virus) [90] and 
HCV (Hepatitis C Virus)  [91], among the others, use 
macropinocytosis as additional entry pathways. 
These different routes (CME, CDE, non-clathrin non-
caveolae endocytosis and macropinocytosis) result in 
different internalization yields and may be related to the 
different degrees of virulence and pathogenicity of influ-
enza strains [92].
Endosomal trafficking
After attaching to the respiratory cell surface, the influ-
enza virus, as already mentioned, can penetrate into the 
cell through more than one mechanism, and the final re-
sult is that the virions are internalized in an endosomal 
compartment  [93]. According to the previous routes, 
virions can be packaged into CCPs and clathrin-coated 
vesicles (CCVs) or into caveosomes / macropinosomes. 
Subsequently, they are further processed into early en-
dosomes (EEs) and into late endosomes (LEs) [94].
Endosomal trafficking usually follows influenza virus 
uptake. Virions are taken up into Rab-5/Vps4 and Rab-
7/LAMP (lysosomal-associated membrane protein) pos-
itive endosomes. Rab-5/Vps4 and Rab-7 are Rab guano-
sine triphosphatases (GTPases) that are responsible for 
the processes of trafficking and fusion for EEs and LEs, 
respectively [95-97]. 
LAMPs are a series of proteins –  3 isoforms are cur-
rently known, namely, LAMP1 (known also as 
CD107a), LAMP2, and LAMP3 (DC-LAMP, TSC403 
or CD208)  –  that are involved in endosomal matura-
tion [98]. Moreover, the expression of LAMP3 has been 
found to be predictive of the host’s response to influ-
enza [99].
Cullin-3 (Cul3) belongs to the Cullin-RING-ligase fam-
ily (CRL). It functions as a scaffolding protein in the 
Bric-a-brac, Tramtrack, Broad-complex (BTB)-Cul3-
Rbx1 ubiquitin E3 ligase complex and is involved in LE 
maturation and cargo trafficking [100, 101].
Endosomal trafficking is a complex multifaceted pro-
cess that can be divided into three stages: stage I, which 
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is actin-dependent, stage II, which is dynein- and micro-
tubule-dependent, and stage III, which is microtubule-
dependent [102].
Influenza envelope fusion
In order for the virus to emerge from the endosome and 
for ribonucleoprotein (RNP) to be released into the cy-
tosol, the envelope must fuse with the endosome mem-
brane. This part of the life-cycle of the virus requires the 
acidity of the lumen of the endosome to decrease to a 
pH value of about 5 [103, 104]. In this process, a crucial 
role is played by M2, which not only acts on ion chan-
nels, thereby allowing acidification of the interior of the 
virus [105], but also alters its conformation, resulting in 
changes of the curvature of the viral envelope [106, 107]. 
This leads to two important events, namely: the dis-
sociation of the M1 protein from RNP and a dramatic 
change in the conformation of HA [108], which can ex-
pose its fusion peptide. This peptide may allow fusion 
of the viral envelope and the endosome membrane and 
the release of RNP into the cytoplasm. The cleavage of 
HA occurs through a proteasic enzymatic action [109]. 
Proteases that can cause the cleavage of HA are widely 
distributed throughout the human body, and the precise 
role that each plays in cutting the HA is not exactly 
known. Nevertheless, proteases are known to belong to 
two main classes, namely trypsin-like enzymes or furin-
like serine enzymes [109]. These enzymes are produced 
by the cells, particularly those of the respiratory system, 
in the presence of inflammation (proinflammatory cy-
tokines/chemokines, neutrophils, etc.) [110]. 
The release of RNP into the cytosol is also enabled by 
the host’s aggresome processing machinery (made up 
of dynein, dynactin and myosin II) [111]. Further mol-
ecules and pathways could take part in this process.
M2 is more than just a simple ion channel. Indeed, it 
plays a multifaceted role in the entire viral life-cycle, as 
the mechanism of proton permeation, conductance and 
acidification is crucial to each different step and activity 
of the virus. After endocytosis, the low endosomal pH (in 
the range 5-6) activates the M2 channel prior to HA-me-
diated fusion, and favours dissociation of the M1 protein 
from the vRNPs, thereby facilitating the entry of RNPs 
into the nucleus. M2 is fundamental to genome unpack-
ing and the release of the viral RNA during viral uncoat-
ing [112]. Moreover, M2 enables the viral RNA to pack-
age and facilitates virion scission and budding during 
viral maturation and assembly, replication and infection: 
during transport to the cell surface, in the trans-Golgi 
network (TGN) membrane, M2 acts as a proton-leak 
channel and prevents the activation of de novo synthe-
sized HA by regulating the pH of the Golgi apparatus of 
the host cell and equilibrating its pH with the pH of the 
viral interior. Indeed, if it were not elevated in this way, 
the low pH would cause a conformational rearrangement 
of HA, whose intracellular cleavage would prematurely 
inactivate the new influenza viral progeny  [113, 114]. 
M2, together with other proteins such as NS1 and HA, 
could play an additional role of fine-tuning the apoptosis 
of infected cells, thus favouring viral replication [115]. 
NS1 is involved in several biological tasks, such as 
mRNA splicing and translation, cell survival, and im-
mune defence. In particular, as far as the type I interfer-
on (IFN-I)-mediated response is concerned, it interacts 
with PACT/PRKRA (Protein activator of the interfer-
on-induced protein kinase / Protein kinase, interferon-
inducible double stranded RNA dependent activator), 
which is an important cofactor for the IFN-I response 
elicited by the viral RNA-sensor RIG-I (Retinoic acid-
Inducible Gene I). Therefore, it blocks PACT/RIG-I-
mediated activation of IFN-I  [116, 117]. Moreover, it 
binds latent protein kinase PKR (Protein Kinase R, also 
known as Protein kinase RNA-activated or interferon-
induced, double-stranded RNA-activated protein kinase, 
or eukaryotic translation initiation factor 2-alpha kinase 
2 – EIF2AK2), whose activation would inhibit viral pro-
tein translation and synthesis  [118], and also TRIM25 
(tripartite motif-containing protein 2)  [119, 120]. Re-
cently, it has been shown to interact with an array of host 
proteins, such as interleukin-6 receptor (IL-6R), MHC 
class I HLA-B, cathepsin B, ubiquitin, and adenosine 
deaminase acting on RNA (ADAR1) [121].
With regard to M2 ion channel activity, the heart of this 
mechanism is the HxxxW motif of the inner transmem-
brane (TM) residues  [122-125]. In this HxxxW motif, 
Histidine 37 putatively acts as the pH sensor and, when 
the pH is low, the protonation of the imidazolic ring 
destabilizes TM packing because of electrostatic re-
pulsion. Tryptophan 41, which acts as a primary gate, 
rotates, becomes unlocked from Aspartic acid 44 (“the 
channel lock”) and, being now parallel to the axis of 
the pore, makes the protons flow. By contrast, Valine 
27 acts as a secondary gate (the so-called “Valine 27 
valve”); its importance has been confirmed only recently 
by the multi-scale simulation carried out by Liang and 
coll. [126]. On the basis of the exact role of the Histidine 
37 tetrad, two models have been proposed: the shutter 
model, in which the biprotonated charge of Histidine 37 
does not change during the proton flux (proton diffu-
sion is coupled with water wire via the Grotthuss mecha-
nism), and the shuttle model, in which the protonation 
status of Histidine 37 is subject to changes during excess 
proton transfer [127]. However, the exact mechanism of 
highly selective transport of protons is not known.
Acidification is enhanced by the viral activation of the 
PI3K cascade [76].
Nuclear importation 
The next event in replication is the importation of RNP 
into the nucleus. The trafficking of RNP into the cyto-
plasm is achieved extremely rapidly, by means of a mech-
anism of diffusion, without the intervention of microtu-
bules, intermediate filaments or actin filaments, through 
the nuclear pore complex (NPC). Some important com-
ponents of the NPC are the nucleoporins Nup37, Nup43, 
Nup45 [128], Nup50 [129], Nup54 [130], Nup58 [128], 
Nup62 [131], Nup75, Nup88, Nup93, Nup98, Nup107, 
Nup133  [128], Nup153  [132-135], Nup160  [128], 
Nup214 [130], NuTF2 (Nuclear Transport Factor 2) and 
Nup358/RanBP2 [128]. 
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Nup37, Nup88, Nup96, Nup107, Nup133 and Nup160 
belong to the so-called Nup107 subcomplex  [136], 
while NupL1 (Nup45/Nup58), Nup54, and Nup62 be-
long to the Nup62 subcomplex [137]. Other components 
are Magoh, ALADIN, Tpr (Translocated promoter re-
gion), EJC (exon junction complex), NLP1/CG1 (Nu-
cleoporin-Like Protein type 1), Seh1, Rae1/Gle2 and 
POM121 (nuclear envelope pore membrane protein type 
121) [128].
When RNPs reach the nuclear membrane, nuclear 
importation is mediated by the binding of the nu-
cleoprotein with the alpha importins, which then bind 
importin-β  [129]. Simultaneously, the importins must 
interact with PA, PB1 and PB2 [130], and this affects the 
interaction of the RNP with the same importins  [131]. 
Specifically, subunits PB1 and PA are imported by Ran-
BP5 or karyopherin beta3 (also known as importin beta3, 
or importin 5), whilst subunit PB2 is imported by impor-
tin alpha-3 or importin alpha-7. NPs are imported by im-
portin alpha-1 [132-141]. Other molecules that take part 
in nuclear importation are Hsp70 and Hsp90 [142-144]. 
In the nucleus, the importins detach from RNP. Al-
though it is not clear, nor is the mechanism known at 
the molecular level, dissociation of the RNP should oc-
cur after separation from the importins. Thus, after the 
spreading of RNP in the nucleoplasm, transcription and 
replication can initiate. 
Transcription and replication
The transcription and replication of viral nucleic acid are 
not fully understood. However, the phenomena involve 
coordinated and differentiated RNA, NP and RdRp ac-
tivities. The package that consists of the genomic seg-
ments (sRNA), the unit of trimeric polymerase and the 
nucleoprotein is the elementary replication unit of the 
influenza virus (vRNP). Therefore, in the nucleoplasm, 
vRNP needs to trigger the first round of its replication 
cycle, i.e. copying its genomic information onto mR-
NAs. Subsequently, mRNA exportation occurs in the 
cytoplasm. 
The influenza polymerase is a heterotrimeric ~250 kD 
complex. It plays central roles in the viral life-cycle and 
is directly responsible for RNA synthesis for both viral 
replication and transcription. Moreover, it recruits host 
factors such as DnaJA1/Hsp40 [145].
The PA subunit interacts with host factors such as the 
mini-chromosome maintenance complex (MCM, a puta-
tive DNA helicase) and hCLE/CGI-99 [146, 147]. The 
PB2 subunit binds to the host RNA cap (7-methylguano-
sine triphosphate (m(7)GTP)) and supports the endonu-
clease activity of PA in order to “snatch” the cap from 
host pre-mRNAs  [148, 149]. Moreover, PB2 interacts 
with the acetyl-CoA found in eukaryotic histone acetyl-
transferases (HATs) [150]. 
Viral mRNA synthesis is initiated by a cis-acting viral 
RNA polymerase, which is part of the vRNP structure 
and is bound to the vRNA promoter. However, mRNAs 
are not able to translate the genetic message efficiently; 
indeed, they need to be capped. Specifically, the virus 
must use the pre-mRNA of the cell and, for this purpose, 
a coordinated process mediated by PB2, PA and the cel-
lular Polymerase II (Pol II) is necessary. Very briefly, 
PB2 binds mRNAs with cellular Pol II and PA, which, 
by means of an endonuclease mechanism, generates 
capped-mRNAs, which are translatable at the ribosomal 
level. 
According to a model proposed by Fodor [151], a trans-
acting polymerase activity is necessary for vRNA rep-
lication. Because of the negative polarity of vRNA, 
positive RNA (cRNA) must be synthesized from the 
mRNA templates. The replication of vRNA could then 
be performed by a trans-acting RNA polymerase, which 
may be distinct from the polymerase in the packages of 
RNPs. Various hypotheses have been formulated re-
garding the proteins, for instance NPs, that trigger trans-
acting polymerase [152, 153]. Although this assumption 
is contradicted by other studies, which have shown viral 
replication in the absence of NP [154], the presence of 
newly synthesised NPs appears to be important in sta-
bilizing the length of the segments of viral RNA. Fur-
thermore, other studies have suggested that NEP could 
regulate viral RNA synthesis [155]. The importation of 
newly synthesised nucleoproteins and polymerases is 
also very important in order to assemble nucleoprotein 
with the negative-sense viral RNA. This event is not 
completely understood and requires coordinated interac-
tion between Nuclear Localisation Signals (NLSs), PA, 
PB1, PB2, NP and importins [156-158]. In addition, as 
recent research has demonstrated [159, 160], NP plays a 
major role in the assembly of vRNP by interacting with 
polymerase subunits and is involved in the nuclear and 
cytoplasmatic transportation of vRNP. Specifically, NPs 
are oligomerized in ring structures, which interact with 
viral RNA segments and also with polymerase trimers. 
This latter interaction allows the viral RNA to twist into 
a double helix with the polymerase complex at one ter-
mination, and with a loop of RNA at another termina-
tion [161-164].
To progress, the infection requires a coordinated two-
way flow between proteins synthesized in the cytoplasm 
(for instance M1 protein and NP) and the viral RNA that 
has been replicated in the nucleus. In this way, the RNP, 
which is full of vRNA, NP, M1, PA, PB1, PB2, and the 
non-structural proteins can reconstitute in the nucleus. 
The transcription factory is made up of components 
such as SFPQ/PSF (splicing factor proline-glutamine 
rich  [164], though its entire molecular anatomy is not 
known. As already mentioned, splicing mechanisms are 
crucial to increasing the dynamism and complexity of 
the influenza proteome. Specifically, the RED-SMU1 
spliceosomal complex interacts with PB1 and PB2 and 
is responsible for the splicing of NS1. Other compo-
nents of the spliceosomal complex are: EJC, SR (ser-
ine/arginine-rich proteins, such as SRp40, SRp55 and 
pre-mRNA Splicing Factor type 2 / Alternative Splicing 
Factor – SF2/ASF), NS1-BP and hnRNP K (heterogene-
ous nuclear ribonucleoproteins K) [165-168].
Transcription and replication are enhanced by activation 
of the PI3K cascade via NS1 [76].
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Nuclear exportation 
Subsequently, through more than one mechanism, such 
as that of small proteins capable of passing through the 
nuclear pores easily, NS1 and NEP/NS2, the RNP com-
plexes can be exported into the cytoplasm. 
The export machinery is a factory made up of several com-
ponents: E1B/AP5, Rae1/mRNP41  [132], NXF1-TAP 
(Nuclear RNA export factor type 1) [133], CBC (nuclear 
cap-binding complex, in particular the 80 kDa subunit), 
REF/Aly, TREX, P15-INXT, YB-1 (Y-box-binding pro-
tein type 1), CRM1/XPO1 (exportin type 1) [169], Rcc1 
(Regulator of chromosome condensation type 1), CHD3 
(chromodomain helicase DNA-binding protein type 3), 
RMB15B [170], RanBP3  [171], DDX19B, an ATP-de-
pendent RNA helicase [172], and Hsc70 (heat shock cog-
nate protein 70) [173] among others. 
Briefly, two main export routes can be described: the 
NXF1-dependent and the CRM1-dependent pathways. 
RNPs are exported via CRM1, whilst HA, NA are trans-
ported by NXF1.
CRM1 pathway includes: Nup88, Nup214, Rcc1, Ran-
BP3, CHD3, Hsc70, NS2, among others [174, 175].
Post-translational processing  
and trafficking
After being translated, proteins are transported to the 
Golgi network, where they are modified. Modifications, 
such as glycosylation of HA and NA, palmitoylation/S-
acylation of HA and M2, phosphorylation of NS1, and 
SUMOylation of M1, NS1, NP, PB1 and NEP by SU-
MO-1/2/3 (Small Ubiquitin-like Modifier type 1/2/3) 
are essential steps in the production of functionally ac-
tive viral proteins [176]. These tasks are performed by 
kinases, such as Cyclin-Dependent Kinases (CDKs) and 
extracellular signal-regulated kinases (ERKs) [177].
Proteins are retrogradely transported by COPI and Rab8 
from the trans-Golgi apparatus to the cis-Golgi and 
ER [178].
The quality of protein folding and the correctness of post-
translational processing are checked by proteins such as 
malectin, calnexin, calreticulin and ERp57 [179-183]. 
Apoptosis pathway
The exportation of RNPs is favoured as the infection 
progresses, which results in activation of the mechanism 
of spontaneous cell death (apoptosis) through the activa-
tion of caspase 3  [184]. By altering the nuclear mem-
brane, the activation of caspase 3 increases perviousness 
through the nuclear pore [185, 186]. Indeed, caspase 
signalling pathways play an important role in the activa-
tion, replication, propagation and pathogenicity of the 
influenza virus, and are therefore related to the severity 
of influenza symptoms and its clinical burden [187]. The 
virus finely tunes and modulates the host cellular pro-
Fig. 2. Chemical structure of the available licensed anti-influenza drugs: m2 blockers (Amantadine, rimantadine), Neuraminidase inhibitors 
(NAIs; Oseltamivir, Zanamivir, peramivir, Laninamivir), ribavirin and Arbidol. 
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teins involved in the processes of regulation and control 
of the induction of apoptosis [188]. 
The units of RNP released from the nucleus are concen-
trated in the perinuclear cytoplasm  [189], particularly 
in the region of the centre for organizing microtubules 
(MTOC)  [190] and, subsequently, in the area of recy-
cling endosomes (REs) [191]. Interaction with the REs 
allows the RNPs to interact better with the network of 
microtubules, and thus to orient themselves and to travel 
towards the cell membrane  [192]. The exportation of 
RNPs is a complicated mechanism that requires well-
synchronized timing, and results in an accumulation of 
RNPs on the apical surface of the cell in the late stages 
of viral multiplication. 
In the late stages of viral replication, the accumulation of 
HA molecules on the cell membrane, probably by activat-
ing the mitogen-activated protein kinase (MAPK) [193], 
increases the exportation of RNPs, which, through a still 
unknown mechanism, is oriented towards the apical sur-
face of the cell.
Subsequently, as each unit of RNP contains only one 
of the eight segments of the viral genome, it is particu-
larly important that the different segments be assembled 
properly. The viral RNAs themselves mediate this pro-
cess through a “hierarchical assembly” signalling mech-
anism [194]. 
Budding and release
As the infection progresses, the apical membrane be-
comes rich in viral proteins, which together initiate the 
budding of the virus around the complex of RNPs, at 
the regions of the membrane where the extruded HA, 
the NA, and M1 and M2 proteins are concentrated [195]. 
Viral proteins are then delivered to the plasma mem-
brane and assembled. Here, Rab11a  [196] and HRB 
(HIV Rev-binding protein) [197] play an important role.
HA is able to initiate the process of budding, but not to 
complete it. This requires the mediation of NA, M1 and 
M2 proteins [195]. It is also important to consider that, 
during the formation of the positive curvature of the cell 
membrane, the suitably assembled units of RNPs move 
toward the distal part of the viral bud, so that they can be 
properly wrapped by the viral envelope. As the budding 
process progresses, a stalk is generated which holds the 
virion to the cell. The viral envelope must then detach 
itself from the cell membrane. The M2 protein appears 
to be crucial to this process. Indeed, it is capable of gen-
erating a positive curvature of the membrane), which is 
necessary in order to enable the spherical virions to split 
off [195]. However, the virus is not yet free; it is bound 
to the cell by the binding of HA molecules with the units 
of sialic acid of the membrane surface. NA molecules 
must therefore detach the sialic acid from the cell sur-
face in order to accomplish viral budding. 
The enzymatic mechanism of influenza virus sialidase 
has been studied by Taylor, who showed that the enzyme 
catalysis process is particularly complex and consists of 
four steps. During the first step the α-sialoside is dis-
torted from a chair conformation to a pseudoboat con-
formation when the sialoside binds to the sialidase. The 
second step leads to sialosyl cation, an oxocarbocation 
intermediate. The third step is the formation of Neu5Ac, 
as α-anomer. The fourth step involves its mutarotation 
and the subsequent release of the thermodynamically-
stable β-Neu5Ac [198]. Finally, these steps lead to sialic 
acid hydrolysis. 
Currently, 11 isoforms of NA are known; NA10 and 
NA11 have recently been isolated from bats and are not 
able to cleave sialic acid. Their precise role and mecha-
nism are still unknown [54].
NA is further classified into two groups: group 1 (N1, 
N4, N5 and N8) and group 2 (N2, N3, N6, N7 and N9), 
based upon primary sequence [199]. Group 1 NAs con-
tain a 150-cavity (formed by amino acids 147–151 of the 
150-loop), an exposed pocket near the active catalytic 
site, whereas group 2 NAs lack this cavity [200].




Amantadine and Rimantadine (Figs. 2, 3) were the 
first generation of influenza antiviral agents  [203]. 
Amantadine (1-aminoadamantane) is a derivative of 
the hydrocarbon tricyclo[3.3.1.1.3,7]decane. Aman-
tadine can be administered either as a hydrochloride 
derivative (Symmetrel), as 100 mg tablets or syrup, or 
as its effective derivative Rimantadine (α-methyl-1-
adamantanemethylamine hydrochloride, Flumadine). At 
high concentrations, Amantadine and Rimantadine non-
specifically raise the pH within cellular endosomes, thus 
inhibiting or retarding the acid-induced conformational 
change in viral HA. At low concentrations, Amantadine 
and Rimantadine specifically inhibit the ion-channel ac-
tivity of the M2 protein [204]. 
Crossing the brain-blood barrier and being present in the 
cerebrospinal fluid (CSF) with a concentration around 
75% of serum level, Amantadine can also be used to treat 
Parkinson’s disease  [205], depression and obsessive-
compulsive disorder (OCD)  [206], Huntington’s dis-
ease [207], attention deficit hyperactivity disorder (AD-
HD) and other neuropsychiatric diseases [208], cocaine 
abuse and dependence  [209], HCV [210], Creutzfeldt-
Jakob’s disease [211], Borna’s disease [212], herpes and 
post herpes zoster neuralgia (PHN) [213]. 
This variety of uses seems to suggest that Amantadine, 
besides blocking the M2 channel, acts on an array of 
receptors, from the dopaminergic receptors to noradr-
energic, serotoninergic, cholinergic, and N-Methyl-D-
aspartate (NMDA) receptors [214, 215]. 
After being rapidly adsorbed, with an excellent bioavail-
ability profile (usually in the range 86-94%) [216], the 
drug reaches peak plasma levels within 4 hours  [216]. 
The plasma elimination half-life is about 11–15 h in pa-
tients with normal renal function. It has a plasma protein 
binding of about 67% [216].
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The drug, after being poorly metabolized and being 
widely distributed, is almost completely excreted via 
glomerular filtration and tubular secretion: this implies 
a dose adjustment when administered to patients with 
renal failure or to the elderly, such as reducing the daily 
dose of 100 mg, instead of 200 mg.
Acting on muscarinic receptors, some patients may 
experience anti-muscarinic adverse effects such as or-
thostatic hypotension, gastrointestinal discomfort (nau-
sea, vomiting, anorexia), congestive heart failure [216]. 
Moreover, because Amantadine has some Central Nerv-
ous System (CNS) stimulatory properties, adults may 
complain of confusion, disorientation, jitteriness, anxi-
ety, mood disorders, slurred speech, insomnia, ataxia, 
tremors, and, rarely, nightmares, oculogyric episodes. 
These symptoms are usually more common (up to 15-
30%) when the drug is used for different weeks for pro-
phylactic purpose. When instead used for treatment (less 
than a week), it is better tolerated. In rare cases, seizures, 
hallucinosis/hallucinations, coma, acute psychosis and 
cardiac arrhythmia may occur, usually in patients with 
underlying psychiatric comorbidities  [216, 217]. Adult 
Respiratory Distress Syndrome (ARDS) has been rarely 
and anecdotally reported [218].
Crossing the placenta and being present in breast milk, 
it is teratogenic at least in animals, even though safety 
has not been established in pregnant women: for precau-
tion sake, it belongs to class C. Pregnancy is recognized 
as one of the risk factors for catching influenza and un-
toward outcomes (higher morbidity, hospitalization and 
mortality rates), but cannot benefit from adamantanes. 
Also in children and in the elders, the effectiveness in 
preventing, treating and shortening the duration of in-
fluenza A appears to be limited, according to a recent 
systematic review [219].
Rimantadine can be administered as 100 mg tablets. It 
reaches peak plasma concentration after 3-6 hours. The 
plasma half-life is long (24-36 hours). Rimantadine is 
more metabolized than Amantadine: only 25% is secret-
ed unchanged [216]. It has a plasma protein binding of 
about 40%.
Fig. 3. Schematic representation of the sites of action of anti-influenza licensed drugs. The steps of the replication cycle of the influenza 
virus are the following: 1) attachment of the virion to target cells and receptor binding (virus adsorption); 2) internalization into cellular 
regions by means of clathrin-mediated endocytosis (Cme), caveolae-dependent endocytosis (Cde), clathrin-caveolae-independent endocy-
tosis, and macropinocytosis; 3) endosomal trafficking via endosomes / caveosome / macropinosome / lysosomes to the perinuclear com-
partment; 4) ph-dependent fusion of viral and endosomal / organellar membranes; 5) uncoating; 6) nuclear importation; 7) transcription 
and replication; 8) nuclear exportation; 9) protein synthesis; 10) post-translational processing and trafficking; 11) viral progeny assembly and 
packaging; 12) budding; and 13) release. Abbreviations: NAIs (neuraminidase inhibitors).
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Rimantadine is characterized by lower rates of 
ADRs [220]: compared to Amantadine, it is better toler-
ated by children and the elderly. 
Unfortunately, the use of M2 inhibitors has been limited 
by the emergence of drug-resistant strains of influenza 
viruses [221], such as the mutations of pore-facing resi-
dues (V27A, A30T, S31N, G43E), mutations of close 
interhelical residues located at the N-terminal half of 
the channel (L26F), and mutations of far interhelical 
residues far located at the C-terminal half of the channel 
(L38F) [221-222].
Na Inhibitors
In recent times, the most widely used antivirals against 
influenza have been the inhibitors of Neuroaminidase: 
namely Oseltamivir and Zanamivir (Figs. 2, 3). From a 
chemical point of view, NA inhibitors can be classified 
into: sialic acid derivatives (or 5,6-dihydro-4H-pyran 
derivatives), benzoic acid derivatives, cyclohexene de-
rivatives, cyclopentane derivatives, pyrrolidine deriva-
tives and natural products. The first NA inhibitors were 
representatives of the first chemical class, being unsatu-
rated syalic acid analogs, such as DANA and FANA, 
which were initially described by Meindl and Tuppy in 
1969 [223]. 
NA is a homotetrameric enzyme of about 220-240 kDa 
that is essential to the reproduction of the influenza vi-
rus. Indeed, it exerts at least three crucial actions. First, 
neuraminidase frees the virus from the respiratory mucus 
and allows it to reach the cells of the respiratory mucosa 
more easily. The coordinated action of HA, NA, M1 and 
M2 is required during the phase of viral budding. Fi-
nally, NA is required in order to release the virus from 
the cell surface by cutting the molecules of sialic acid 
that still anchor the virus to the cell surface by means of 
HA after completion of the replication cycle. This action 
also facilitates separation of the self-aggregated virions 
of the viral progeny. Burnet and coll. [224] first had the 
idea that an inhibitor of NA could be an effective anti-
viral agent, but only when the crystal structure of NA 
and its complex with neuroaminic acid were defined by 
Coleman in 1993 was it possible for von Itzstein [225] 
to synthesize a neuroaminic acid derivative with an 
enhanced affinity for influenza NA. This compound is 
Zanamivir (4-guanidino-Neu5Ac2en, or 4-GU-DANA). 
Its mechanism of action, which is identical to that of Os-
eltamivir, is characterized by the fact that the molecule 
mimics sialic acid; thus, it enters into competition with 
the acid and reversibly binds the molecules of viral NA. 
Zanamivir was designed to concentrate locally in the res-
piratory tract, while Oseltamivir (GS4104) was designed 
to have a high bioavalability (80%) concentration after 
oral administration. Indeed, Oseltamivir is very well 
absorbed from the gastrointestinal tract and is rapidly 
metabolised to active Oseltamivir carboxylate (GS4071) 
([3R,4R,5S]-4-acetamido-5-amino-3-(1-ethylpropoxy)-
1-cyclohexene-1-carboxylate phosphate) in the liver 
by hepatic carboxyl-esterase 1. The active metabolite 
is distributed throughout the body, including the upper 
and lower respiratory tract, middle ear, tracheal lining, 
nasal mucosa and lungs  [226]. Plasma half-life varies 
from 1-2 to 3-4 hours, being 6-10 hours for the carboxy-
late form [226]. Oseltalmivir is extensively metabolized 
(more than 95%).
Oseltamivir and Zanamivir result comparable in terms of 
clinical profile and superior to the adamantanes [227, 228]. 
Regarding the clinical effectiveness of the two drugs, a 
recent meta-analysis by Jefferson et al.  [229] revealed 
that both drugs had a modest therapeutic effect in 
healthy adults and that prophylactic treatment with ei-
ther Zanamivir or Oseltamivir was effective in prevent-
ing the disease.
Zanamivir is supplied in “Rotadisks” with four blisters 
containing 5 mg of powder each. Five Rotadisks are 
packaged with a Diskhaler inhalation device. Oseltami-
vir is available as 75 mg capsules or as an oral suspension 
containing 12 mg/mL (Oseltamivir phosphate) [217].
ADRs are usually nausea, vomiting. Recently, CNS tox-
icity in infants younger than one year of age has been 
reported [217]. 
While adjustments are necessary in subjects suffering 
from renal failure, no adjustments are needed in patients 
with hepatic failure or mild obesity. Oseltamivir can be 
administered to pregnant women [230]. 
While the majority of currently circulating influenza viral 
strains are resistant to amantadanes, the resistance of both 
H1N1 and H3N2 strains and of type B viruses to Oseltami-
vir and Zanamivir is very low. For this reason, the US CDC 
and the WHO recommend their use for the treatment and 
prevention of seasonal and pandemic influenza [231, 232]. 
Other licensed drugs
Other NAIs
Two analogues of Zanamivir and Oseltamivir, which are 
currently licensed in Japan and other Asian countries, 
are Peramivir and Laninamivir octanoate hydrate (CS-
8958) (Figs. 2, 3). 
The former is only administered intravenously because 
of its very poor bioavailability  [233]. It has been li-
censed in Japan and in South Korea, but was only tem-
porarily approved for emergency use in the USA during 
the H1N1 pandemic [234]. 
The latter drug is very promising because of its long-acting 
inhibitory effect [235]. Inavir was launched in Japan in Oc-
tober 2010 as a 20-mg dry powder inhaler. It is a prodrug 
that is converted in the airway to laninamivir (R-125489), 
the active NAI and is retained at high concentrations for 
at least 10 days after a single inhalation of 40 mg. Only 
15% of the drug is orally bioavailable [223]. Commonly 
reported ADRs were psychiatric, gastrointestinal and CNS 
disorders [223]. A single inhalation dose makes Inavir a 
quite convenient drug, even though children and young 
adolescents could not inhale it properly [232].
Ribavirin
Considering the compounds targeted against the tran-
scription and replication of vRNA, one of the first de-
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veloped drug is Ribavirin (Figs. 2, 3). Ribavirin, also 
known as the trade name of Virazole, is the guanosine 
nucleoside analog: 1β-D-ribofuranosyl-1,2,4,-triazole-
3-carboxamide. Its mechanism of action is not com-
pletely known. However, Inosine 5’-monoposphate 
dehydrogenase (IMPDH) appears to be the principal 
target of the molecule [234]. This inhibition diminishes 
the intracellular concentration of GTP (Guanosine-5’-
triphosphate), and this would stop viral protein synthesis 
and limit the vRNA replication. Crotty et al also demon-
strated that Ribavirin is a vRNA lethal mutagen, resem-
bling guanosine or adenosine and causing mutations in 
RNA replication [235]. However, the need of high doses 
of the drug to have good clinical results have limited the 
use of Ribavirin as anti-influenza drug, and a recent re-
vision of the literature by Chan-Tack et al. suggests that 
there are not conclusive results about the beneficial use 
of Virazole for treatment of influenza [236]. 
Ribavirin can be administered orally, by aerosolization, 
rarely by intravenous route [237]. ADR is dependent on 
the administration route, being extravascular haemolytic 
anemia if the drug is delivered intravenously, a bron-
chospasm if aerosolized [216].
Arbidol
There are several potentially effective drugs, which act as 
HA inhibitors. However, only one medication, the small in-
dole derivative Arbidol (ARB) or Umifenovir (Figs. 2, 3), 
or ethyl-6-bromo-4-[(dimethylamino)methyl]-5-hydroxy-
1-methyl-2[(phenylthio)methyl]-indole-3-carboxylatehy-
drochloride monohydrate, has been licensed [232-248]. 
ARB was created by the Center for Drug Chemistry in 
Moscow [246], has been licensed in Russia 20 years ago 
and since 2006 has been used in China for the prophy-
laxis and treatment of pneumonia caused by influenza 
viruses A and B [234]. ARB probably exerts a multiple 
antiviral action: a direct virucidal effect, a block of the 
virus at the level of cell-entry (attachment and internali-
zation), and impairment of viral replication, because of 
its ability to bind with proteins and lipids  [232-248]. 
Several studies have demonstrated that ARB is also ef-
fective against other enveloped and non-enveloped vi-
ruses, such as Hepatitis B Virus (HBV), HCV, RSV, 
some Picornavirus (such as rhinovirus 14), Poliovirus 
1, Coxsackievirus B5), parainfluenza type 3 (PIV3), as 
well as the avian coronavirus, infectious bronchitis vi-
rus, Chikungunya virus, Reovirus, Hantaan virus, Ve-
sicular stomatitis virus (VSV) and Marek disease virus, 
an avian oncogenic herpesvirus [234].
It is metabolized in the liver and redistributed in the 
body tissues. 
The principal biotransformation pathways include sul-
foxidation, dimethylamine N-demethylation, glucuroni-
dation, and sulfate conjugation. The major metabolite is 
sulfinylarbidol, followed by unmetabolized arbidol, N-
demethylsulfinylarbidol, and sulfonylarbidol. CYP3A4 
is the major isoform involved in ARB metabolism, 
whereas the other P450s and flavin-containing monoox-
ygenases (FMOs) play minor roles. Plasma half-life is 
long (up to 25 hours) [243].
Conclusions 
In recent decades, few antiviral drugs against influenza 
virus infections have been available. This has limited 
their use in human and animal outbreaks. Indeed, antivi-
ral drugs used during seasonal and pandemic outbreaks 
have usually been administered as mono-therapy and, 
sometimes, in an uncontrolled manner in farm animals. 
This has led to the emergence of viral strains that are 
resistant, especially to the compounds of the amanta-
dane family. For this reason, it is particularly important 
to develop new antiviral drugs against influenza viruses. 
Indeed, although vaccination is currently the most effec-
tive means of mitigating the effects of influenza epidem-
ics and can delay the spread of new pandemic viruses, as 
maintained by the Advisory Committee on Immuniza-
tion Practice (ACIP), antiviral drugs can be very use-
ful in allowing manufacturers to prepare large quantities 
of pandemic vaccines. In addition, antiviral drugs are 
particularly valuable in complicated cases of influenza, 
particularly in hospitalized patients and in individuals at 
risk, such as the elderly or patients with chronic respira-
tory diseases. In such cases, it would be particularly de-
sirable to have more antivirals and to administer them in 
an appropriate manner [249, 250]. 
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